Unstable angina

Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, FDA, Professional Services, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Legal, Science, Growth, Patent, CKD, Risk, Diabetes, AKI, Patient, Ageing, Trimetazidine, Acute kidney injury, MD, IND, Therapy, PCI, Safety, Chronic kidney disease, Unstable angina, Percutaneous coronary intervention, Pharmaceutical industry

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that it has received a Notice of Allowance from the Japanese Patent Office for a patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that it has received a Notice of Allowance from the Japanese Patent Office for a patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.
  • The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes.
  • "We are excited about the continued growth of Saghmos’ patent estate, with an issued US patent and Notices of Allowance for a second US patent and a Japanese patent,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Retrieved on: 
Wednesday, February 21, 2024
FDA, Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Division, Multimedia, Unstable angina, MD, Drug development, Risk, Safety, Therapy, Nephrology, Disease, Percutaneous coronary intervention, Patient, Acute kidney injury, AKI, Shirin David, Trimetazidine, IND, Mortality, Circulatory system, PCI, Pharmaceutical industry

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.
  • Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA.
  • His guidance and his wealth of regulatory experience in the cardio-renal area at the FDA will tremendously benefit our mission to bring ST-62516 to patients,” said Anna Kazanchyan, MD, Founder and CEO of Saghmos.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

Retrieved on: 
Wednesday, February 7, 2024
Cardiology, Biotechnology, Pharmaceutical, General Health, Health, FDA, Health Technology, Other Health, Acute kidney injury, MD, Percutaneous coronary intervention, AKI, IND, Patient, Safety, Trimetazidine, Ageing, CKD, Therapy, Diabetes, Risk, Patent, Chronic kidney disease, Unstable angina, PCI, Pharmaceutical industry

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.
  • "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516.
  • Saghmos continues to build its intellectual property estate,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Liver, Coronary thrombosis, INN, Risk, Pulmonary embolism, STEMI, ATC, DVT, Unstable angina, Bleeding, International, ASA, Myocardial infarction, Antithrombin, Language, Heart, Stroke, European Medicines Agency, Infection, Extracorporeal, Sodium oxide, Rheumatology, Select, Chest pain, Patient, Aspirin, Vein, Safety, Anatomy, Medicine, Leg, Deep vein thrombosis, IIA, Sodium, Skin, Birth control

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

ACTG Announces Publication of REPRIEVE Trial in New England Journal of Medicine and Presentation at IAS 2023

Retrieved on: 
Monday, July 24, 2023
The New England Journal of Medicine, National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, MACE, Bangladesh Technical Education Board, ViiV Healthcare, Risk, IAS, Infection, Unstable angina, Science, University, HIV/AIDS research, AIDS Clinical Trials Group, Myocardial infarction, Disease, Stroke, Cardiovascular disease, Splenic infarction, ART, Death, NIH, Conference, Regius Professor of Medicine and Therapeutics, Gilead Sciences, Hepatitis B, University of California, Calcium, AIDS, Tuberculosis, NIAID, Research, HIV, Hospital, National Heart Foundation of Australia, Lung, Harvard Medical School, NHLBI, ACTG, Female, Pharmaceutical industry

Today’s publication coincides with the symposium “The REPRIEVE trial: Developing a Cardiovascular Disease Prevention Strategy for People Living with HIV,” taking place today at IAS 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia.

Key Points: 
  • Today’s publication coincides with the symposium “The REPRIEVE trial: Developing a Cardiovascular Disease Prevention Strategy for People Living with HIV,” taking place today at IAS 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia.
  • “REPRIEVE is an extraordinarily important study because it addresses the need for interventions to prevent cardiovascular events in people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • The 35 percent reduction in MACE was consistent across key study groups, including sex, race, and global burden of disease region.
  • These conclusions are based on a review of the data by an Independent Data and Safety Monitoring Board, which stopped the trial early.

Milestone Study Exploring the Significant Impact of ED Drugs on Men’s Cardiac Health Published in the Journal of Sexual Medicine

Retrieved on: 
Tuesday, January 17, 2023
Research, Men, Cardiology, Health, Consumer, Pharmaceutical, General Health, Other Science, Science, University of California, San Francisco, ED, Cardiovascular disease, Sildenafil, HMRI, University, Record, Tadalafil, Death, Angioplasty, MD, Huntington Medical Research Institutes, MACE, Medicare, Manuscript, Risk, Diabetes, Mortality, Heart failure, Vardenafil, Unstable angina, Degenerative disease, PDE5, Doctor of Philosophy, Keck School of Medicine of USC, Erectile dysfunction, Pharmaceutical industry, Sanofi, Medicine

This study marks a significant medical milestone, as it’s the first time the association between the use of PDE-5i drugs and cardiovascular health has been explored in a large population of relatively low-risk men with ED in the United States.

Key Points: 
  • This study marks a significant medical milestone, as it’s the first time the association between the use of PDE-5i drugs and cardiovascular health has been explored in a large population of relatively low-risk men with ED in the United States.
  • In this study, scientists analyzed health records of more than 70,000 men with ED.
  • The study, funded by a grant from Sanofi , examined records over approximately 14 years.
  • The overall benefit in reduction of cardiac events was observed in men who also had risk factors for cardiovascular disease including diabetes.

Huntington Medical Research Institutes Present First-of-its-Kind Study Examining Impact of Erectile Dysfunction Drugs on Major Adverse Cardiovascular Events and Mortality

Retrieved on: 
Friday, May 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Men, Health, Consumer, Placebo, MBA, Death, Lists of diseases, ED, Huntington Medical Research Institutes, Population, HMRI, Nationwide Mutual Insurance Company, Tadalafil, Degenerative disease, Doctor of Philosophy, Patient, Migraine, American Heart Association, Solution, Association, Causality, Sildenafil, University of California, San Francisco, American Heart, Vardenafil, Medicare, San Francisco, Research, Erectile dysfunction, Brain, Man, University, Heart failure, Mortality, Heart, Care, Unstable angina, Tablet, Coronary artery disease, Angioplasty, Record, MD, CEO, Pharmaceutical industry, Dietary supplement, Sanofi

Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.

Key Points: 
  • Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.
  • They compared rates of major adverse cardiovascular events (MACE) and death amongst men who took phosphodiesterase type 5 inhibitor (PDE-5i) drugsincluding Viagra, Cialis and Levitrato rates among men who never took these drugs.
  • Since the study was retrospective, Kloner noted that further research is needed to prove that PDE-5i drugs caused the reduction in cardiovascular events that he and his co-investigators observed.
  • Huntington Medical Research Institutes (HMRI) works to improve millions of lives through patient-focused scientific research.

Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome

Retrieved on: 
Wednesday, October 13, 2021
Cardiovascular disease, Company, NDA, Intellectual property, Patient, Center, CHD, IV, Coronary artery disease, Atrial fibrillation, American Heart Association, Heart, Unstable angina, LinkedIn, Mortality, Safety, Chest pain, Industry, Population, Roemheld syndrome, FDA, Cardiology, Cardiac arrest, CM, Issuer, Infarction, Artery, Acute coronary syndrome, Euronext, Myocardial infarction, Partnership, ACS, Moyamoya disease, Pharmaceutical industry

Stijn Van Rompay, Chief Executive Officer of Hyloris, added: Developing an IV formulation of acetylsalicylic acid, the active ingredient of Aspirin, is a challenge due to its inherent chemical instability and poor solubility.

Key Points: 
  • Stijn Van Rompay, Chief Executive Officer of Hyloris, added: Developing an IV formulation of acetylsalicylic acid, the active ingredient of Aspirin, is a challenge due to its inherent chemical instability and poor solubility.
  • We are very pleased to join forces with the team at Rhoshan and implement their breakthrough, proven IV formulation technology to accelerate the development of HY-073, thereby shortening overall timelines.
  • About coronary heart disease (CHD), acute coronary syndrome (ACS) and Aspirin IV U.S.
    CHD occurs when the hearts blood supply is blocked due to the build-up of fatty substances in the arteries around the heart.
  • Rhoshan Pharmaceuticals, Inc is a specialty biopharmaceutical company focused on bringing the first injectable aspirin to US market.

FDA Awards Genetesis Breakthrough Device Designation for CardioFlux® Imaging Technology

Retrieved on: 
Tuesday, December 15, 2020
Cardiology, Technology, FDA, Health, General Health, Radiology, Other Science, Medical devices, Software, Hospitals, Science, Circulatory system, Cardiovascular system, Medical emergencies, Clinical medicine, Aging-associated diseases, Acute coronary syndrome, Myocardial infarction, Chest pain, Coronary artery disease, Food and Drug Administration, Electrocardiography in myocardial infarction, Unstable angina

Genetesis, Inc. announced today that its flagship product, CardioFlux, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.

Key Points: 
  • Genetesis, Inc. announced today that its flagship product, CardioFlux, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.
  • To meet the criteria for Breakthrough Designation, CardioFlux demonstrated the potential for providing a safer, more precise, lower cost, and faster diagnosis for non-ST elevated myocardial infarction (NSTEMI) in the emergency room.
  • Genetesis looks forward to this accelerated collaborative dialogue with the FDA in the regulatory process leading to commercialization of CardioFlux as a diagnostic modality.
  • CardioFlux receiving Breakthrough Device Designation is an important step forward for patients presenting to Emergency Departments across the country with acute chest pain.

2019 Update of Upstream Medical Technologies Ltd - Product Pipeline Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 13, 2020
Biotechnology, Health, Cardiology, Medicine, Clinical medicine, Biomarkers, Branches of biology, Chemical pathology, Biotechnology, Unstable angina, Angina, Product pipeline

The "Upstream Medical Technologies Ltd - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Upstream Medical Technologies Ltd - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.
  • Upstream Medical Technologies Ltd (UMT) is a biomarker based testing developer that markets novel biomarkers for cardiac diagnosis.
  • The company offers patented pipeline of products such as BNP-sp, used for diagnoses of unstable angina, CVD, ACS, and others.
  • This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products.